U.S., Sept. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07195604) titled 'A Single Ascending Dose of HRS-2162 in Healthy Subjects' on Sept. 14.
Brief Summary: The study is being conducted to evaluate the safety and tolerability of HRS-2162 injection in a single dose in healthy subjects, as well as the characteristics of PK/PD
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Reversal of Neuromuscular Blockade
Intervention:
DRUG: HRS-2162
HRS-2162
DRUG: Placebo
Placebo
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....